Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness
More News related to BMRN
- BioMarin Pharmaceutical (BMRN) Announces FDA Grants Orphan Drug Designation for 3,4-DAP
- FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
- BioMarin to Present at the NASDAQ OMX 23rd Investor Program
- BioMarin (BMRN) Responds to News of Contamination at Genzyme (GENZ) Plant; Says Aldurazyme, Naglazyme Won't Be Impacted
- Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
More News related to GENZ
- Notable Analyst Rating Changes 12/2: AMR/UAUA, RFMD, STI, SAY, KBH, BBT Upgraded; STZ, MTL, BWP, POM Downgraded
- Hapoalim Securities Initiates Coverage on Genzyme (GENZ) with a Hold; Pipeline Promising, But Near-Term Competition
- Hapoalim Securities Reiterates a 'Buy' on Protalix (PLX); Raises PT in Wake of Pfizer (PFE) Deal
- Baird Reiterates a 'Neutral' Rating on Genzyme (GENZ); Long-Term Implications Still Evolving
- Genzyme (GENZ) Begins Shipments of Cerezyme and Fabrazyme from Allston Plant
More News related to Analyst Comments
- AMR Eagle Holding (AMR) to Acquire 22 CRJ700 Regional Jetliners From Bombardier Aerospace
- Comcast/GE Confirm NBC Universal Deal; 51% Owned by Comcast, 49% by GE
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
Baird said they are buyers of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) on weakness tied to Genzyme Corp. (Nasdaq: GENZ) Allston manufacturing suspension.
The firm notes, "Aldurazyme fill/finish was previously performed at this facility, but BMRN indicates Allston is now a secondary source and an outside, primary source has been validated for some time. Coupling this with BMRN's indication that at least a year's worth of Aldurazyme finished goods inventory is on hand, we see no impact to BMRN's revenue prospects."
Related Categories
Analyst CommentsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
